Sign In
Buy LLY
$1,185.71
-7.09 (-0.594%)
At Close: Aug 07, 2026
Don't Delay! 3 Stocks to Buy BEFORE Q2 Earnings.
03:52pm, Monday, 22'nd Jul 2024
We're still early in the second-quarter earnings cycle. So far, it has mostly been the banks and credit card companies that have reported Q2 results.
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
03:11pm, Monday, 22'nd Jul 2024
Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidat
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
02:53pm, Monday, 22'nd Jul 2024
HC Wainwright analyst initiated coverage on AnaptysBio Inc ANAB, a clinical-stage biotechnology company focused on delivering immunology therapeutics.
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
09:20am, Monday, 22'nd Jul 2024
Eli Lilly is having great success in the market for weight loss treatments. Viking is working on a candidate that could potentially outperform Eli Lilly's.
Eli Lilly Gets Green Light to Sell Weight-Loss Drug in China
01:40pm, Friday, 19'th Jul 2024
Eli Lilly and Co. (LLY) announced on its WeChat account Friday that it has won approval from Chinese regulators to sell tirzepatide for weight loss in the country.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 19'th Jul 2024
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly's weight loss drug tirzepatide gets approval in China
04:42am, Friday, 19'th Jul 2024
Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish rival Novo Nordisk in the
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
05:53pm, Thursday, 18'th Jul 2024
Since the start of 2020, Eli Lilly's ( NYSE: LLY ) stock price chart has been straight up and to the right, up 553% and currently trading at $848.74.
Eli Lilly's stock plunges as investors eye obesity-drug competition
01:21pm, Thursday, 18'th Jul 2024
Eli Lilly & Co.'s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers.
3 High-Flying Stocks That Show No Signs of Slowing Down
09:33am, Thursday, 18'th Jul 2024
The stock market continues to demonstrate strong performance, with the Dow Jones recently achieving a new record high above 40,000 points. Several factors contributed to this upward movement, includin
3 Reliable Blue-Chip Stocks to Buy, Hold and Never Let Go
08:10am, Thursday, 18'th Jul 2024
Blue-chip stocks are considered to be the most reliable stocks in the industry. Whether you are a beginner or a professional investor, there is nothing like putting your money in blue-chip stocks an
Will Eli Lilly Do a Stock Split in 2024?
05:23am, Thursday, 18'th Jul 2024
Eli Lilly's surging valuation has made the case for a stock split. Many growth stocks have deployed stock splits in recent years, including Eli Lilly rival Novo Nordisk.
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
10:41am, Wednesday, 17'th Jul 2024
Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.
Does Roche have weight-loss giants Novo Nordisk and Eli Lilly on the run?
09:53am, Wednesday, 17'th Jul 2024
The potential of a once-a-day pill for obesity unsettled the weight loss stocks. Shares in Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) were off 4% and 2% respectively on news that Roch
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
09:03am, Wednesday, 17'th Jul 2024
Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its ex
